NovelStem International Corp. (NSTM)
USD 0.01
(23.46%)
USD 0.01
(23.46%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -3.78 Million USD | -57.49% |
| 2022 | -422.43 Thousand USD | 14.75% |
| 2021 | - USD | -57.24% |
| 2020 | - USD | 0.0% |
| 2013 | 6.52 Million USD | 16.31% |
| 2012 | -4.27 Million USD | -88.31% |
| 2011 | -5.6 Million USD | 57.15% |
| 2010 | -7.12 Million USD | -365.36% |
| 2009 | -4.64 Million USD | 46.91% |
| 2008 | -6.36 Million USD | 57.76% |
| 2007 | -6.89 Million USD | -146.73% |
| 2006 | -4.54 Million USD | 49.83% |
| 2005 | -8.8 Million USD | 15.9% |
| 2004 | -6.56 Million USD | -61.74% |
| 2003 | -4.05 Million USD | 21.28% |
| 2002 | -64.26 Million USD | 13.91% |
| 2001 | -5.83 Million USD | 68.11% |
| 2000 | -17.15 Million USD | -66.15% |
| 1999 | -14.7 Million USD | -85.25% |
| 1998 | -6.3 Million USD | 22.78% |
| 1997 | -5.3 Million USD | -27.42% |
| 1996 | -6.1 Million USD | 16.22% |
| 1995 | -7.4 Million USD | -19.35% |
| 1994 | -5.9 Million USD | -675.0% |
| 1993 | -800 Thousand USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -144.03 Thousand USD | 0.0% |
| 2024 Q1 | -183.31 Thousand USD | -100.0% |
| 2023 Q1 | -164.79 Thousand USD | -4.5% |
| 2023 FY | - USD | -57.49% |
| 2023 Q2 | -2.71 Million USD | -1549.97% |
| 2023 Q4 | -29.92 Thousand USD | 60.22% |
| 2023 Q3 | -75.2 Thousand USD | 97.23% |
| 2022 Q3 | -206.21 Thousand USD | 10.18% |
| 2022 FY | - USD | 14.75% |
| 2022 Q1 | 171.04 Thousand USD | 231.98% |
| 2022 Q2 | -229.57 Thousand USD | -234.22% |
| 2022 Q4 | -157.69 Thousand USD | 23.53% |
| 2021 Q4 | -129.59 Thousand USD | 2.69% |
| 2021 Q3 | -133.17 Thousand USD | -55.21% |
| 2021 Q2 | -85.8 Thousand USD | -1047.2% |
| 2021 FY | - USD | -57.24% |
| 2021 Q1 | 9059.00 USD | 0.0% |
| 2020 FY | - USD | 0.0% |
| 2013 Q2 | -1.86 Million USD | 4.7% |
| 2013 Q3 | -10.71 Million USD | -473.74% |
| 2013 Q4 | -1.03 Million USD | 90.31% |
| 2013 Q1 | -1.95 Million USD | -258.06% |
| 2013 FY | - USD | 16.31% |
| 2012 FY | - USD | -88.31% |
| 2012 Q3 | -5.63 Million USD | -256.05% |
| 2012 Q1 | -973.71 Thousand USD | 22.24% |
| 2012 Q4 | 1.23 Million USD | 122.01% |
| 2012 Q2 | -1.58 Million USD | -62.43% |
| 2011 FY | - USD | 57.15% |
| 2011 Q3 | 2.56 Million USD | 207.2% |
| 2011 Q2 | -2.39 Million USD | -21.33% |
| 2011 Q1 | -1.97 Million USD | 67.08% |
| 2011 Q4 | -1.25 Million USD | -148.74% |
| 2010 Q2 | 121.21 Thousand USD | 114.59% |
| 2010 Q3 | -359.31 Thousand USD | -396.43% |
| 2010 Q4 | -6 Million USD | -1570.03% |
| 2010 FY | - USD | -365.36% |
| 2010 Q1 | -830.98 Thousand USD | -118.15% |
| 2009 Q3 | -170.45 Thousand USD | -102.99% |
| 2009 Q2 | 5.7 Million USD | 446.85% |
| 2009 FY | - USD | 46.91% |
| 2009 Q1 | -1.64 Million USD | -210.9% |
| 2009 Q4 | 4.57 Million USD | 2786.12% |
| 2008 FY | - USD | 57.76% |
| 2008 Q4 | 1.48 Million USD | 201.18% |
| 2008 Q3 | -1.46 Million USD | -14.28% |
| 2008 Q2 | -1.28 Million USD | 48.74% |
| 2008 Q1 | -2.5 Million USD | -62.08% |
| 2007 Q2 | -432.42 Thousand USD | 76.65% |
| 2007 Q1 | -1.85 Million USD | -459.18% |
| 2007 Q4 | -1.54 Million USD | 17.57% |
| 2007 FY | - USD | -146.73% |
| 2007 Q3 | -1.87 Million USD | -333.08% |
| 2006 Q3 | -1.43 Million USD | -348.58% |
| 2006 FY | - USD | 49.83% |
| 2006 Q4 | -331.18 Thousand USD | 76.89% |
| 2006 Q2 | -319.52 Thousand USD | 88.51% |
| 2006 Q1 | -2.78 Million USD | -1595.45% |
| 2005 Q3 | -1.7 Million USD | -18.05% |
| 2005 FY | - USD | 15.9% |
| 2005 Q4 | -164.04 Thousand USD | 90.39% |
| 2005 Q2 | -1.44 Million USD | 34.4% |
| 2005 Q1 | -2.2 Million USD | 25.07% |
| 2004 Q1 | -1.62 Million USD | -60.88% |
| 2004 Q2 | -807.62 Thousand USD | 50.28% |
| 2004 Q4 | -2.94 Million USD | -219.97% |
| 2004 Q3 | -918.98 Thousand USD | -13.79% |
| 2004 FY | - USD | -61.74% |
| 2003 Q2 | -1.24 Million USD | 4.94% |
| 2003 Q3 | -726.8 Thousand USD | 71.6% |
| 2003 Q4 | 261.88 Thousand USD | -172.44% |
| 2003 FY | - USD | 21.28% |
| 2003 Q1 | -1.33 Million USD | 42.55% |
| 2002 Q1 | -1.33 Million USD | 39.08% |
| 2002 Q2 | 27.36 Thousand USD | 103.3% |
| 2002 Q4 | -2.23 Million USD | -36.49% |
| 2002 Q3 | -59.82 Million USD | -3920.47% |
| 2002 FY | - USD | 13.91% |
| 2001 Q4 | -2.26 Million USD | -74.18% |
| 2001 FY | - USD | 68.11% |
| 2001 Q2 | -972.99 Thousand USD | 41.43% |
| 2001 Q1 | -1.11 Million USD | 65.49% |
| 2001 Q3 | -1.28 Million USD | -59.91% |
| 2000 Q4 | -4.55 Million USD | 19.03% |
| 2000 Q2 | -4.44 Million USD | 9.9% |
| 2000 FY | - USD | -66.15% |
| 2000 Q1 | -4.01 Million USD | -0.38% |
| 2000 Q3 | -4.14 Million USD | -8.32% |
| 1999 Q1 | -1.1 Million USD | 22.22% |
| 1999 Q4 | -9 Million USD | -112.5% |
| 1999 Q3 | -2.7 Million USD | -41.18% |
| 1999 Q2 | -1.9 Million USD | 19.05% |
| 1999 FY | - USD | -85.25% |
| 1998 FY | - USD | 22.78% |
| 1998 Q3 | -1.3 Million USD | 75.0% |
| 1998 Q2 | -1.7 Million USD | -45.45% |
| 1998 Q1 | -1.1 Million USD | 64.52% |
| 1998 Q4 | -2.4 Million USD | -575.0% |
| 1997 Q4 | -3.1 Million USD | -106.67% |
| 1997 Q3 | -1.5 Million USD | -350.0% |
| 1997 Q2 | -1.2 Million USD | 150.0% |
| 1997 Q1 | -1.2 Million USD | 53.85% |
| 1997 FY | - USD | -27.42% |
| 1996 Q1 | -1.2 Million USD | 47.83% |
| 1996 Q2 | -1 Million USD | 8.33% |
| 1996 FY | - USD | 16.22% |
| 1996 Q4 | -2.6 Million USD | -85.71% |
| 1996 Q3 | -1.4 Million USD | -27.27% |
| 1995 FY | - USD | -19.35% |
| 1995 Q1 | 1.6 Million USD | 155.17% |
| 1995 Q4 | -2.3 Million USD | -27.78% |
| 1995 Q3 | -1.7 Million USD | -200.0% |
| 1995 Q2 | 1.8 Million USD | 12.5% |
| 1994 Q2 | -1 Million USD | -1100.0% |
| 1994 Q3 | -1.8 Million USD | -80.0% |
| 1994 Q4 | -2.9 Million USD | -61.11% |
| 1994 FY | - USD | -675.0% |
| 1994 Q1 | 100 Thousand USD | 111.11% |
| 1993 Q4 | -900 Thousand USD | -1000.0% |
| 1993 Q3 | 100 Thousand USD | 0.0% |
| 1993 Q2 | 100 Thousand USD | 0.0% |
| 1993 Q1 | 100 Thousand USD | 0.0% |
| 1993 FY | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| American Bio Medica Corporation | -1.16 Million USD | -225.52% |
| Arrayit Corporation | -3.07 Million USD | -23.016% |
| Atlantic International Corp. | -5.38 Million USD | 29.757% |
| Biocept, Inc. | -30.24 Million USD | 87.481% |
| Bioqual, Inc. | 3.03 Million USD | 224.852% |
| CardioGenics Holdings Inc | -757.37 Thousand USD | -399.858% |
| DermTech, Inc. | -97.89 Million USD | 96.133% |
| Global WholeHealth Partners Corporation | - USD | Infinity% |
| Hangzhou Tigermed Consulting Co., Ltd. | 2.91 Billion USD | 100.13% |
| HTG Molecular Diagnostics, Inc. | -20.24 Million USD | 81.298% |
| iMD Companies, Inc. | -154.65 Thousand USD | -2347.836% |
| IDenta Corp. | 71.58 Thousand USD | 5388.389% |
| Interpace Biosciences, Inc. | 3.83 Million USD | 198.666% |
| Integrative Health Technologies, Inc. | 38.69 Thousand USD | 9884.955% |
| InVitro International | 6680.00 USD | 56773.638% |
| Lumos Diagnostics Holdings Limited | -5.43 Million USD | 30.357% |
| Many Bright Ideas Technologies Inc. | -12.13 Thousand USD | -31099.926% |
| Medical Imaging Corp. | -896.74 Thousand USD | -322.173% |
| Optigenex Inc. | -1.18 Million USD | -219.013% |
| PharmChem, Inc. | 1.05 Million USD | 459.249% |
| Proteome Sciences plc | -1.13 Million USD | -232.964% |
| Response Genetics, Inc | -19.66 Million USD | 80.75% |
| Rennova Health, Inc. | -234.81 Thousand USD | -1512.248% |
| RushNet, Inc. | -614.85 Thousand USD | -515.725% |
| ScreenPro Security Inc. | -3.43 Million USD | -10.216% |
| Stella Diagnostics Inc. | -5.7 Million USD | 33.669% |
| StageZero Life Sciences Ltd. | -10.27 Million USD | 63.138% |
| Todos Medical Ltd. | -9.39 Million USD | 59.7% |